Israel-based generics specialist Teva (NYSE: TEVA) has announced the initiation of a strategic partnership with China-headquartered China Resources Guangdong Pharmaceutical Co., Ltd (CR Guangdong). This collaboration aims to leverage CR Guangdong’s logistics and supply chain management expertise to support the introduction of Teva’s migraine therapy, fremanezumab, in the Greater Bay Area (GBA) of China.
Fremanezumab’s Market Introduction and Approval
Teva’s fremanezumab, a clinically needed drug for the treatment of migraines, received approval in China in July 2023, specifically targeting the GBA region. CR Guangdong, which has been approved by Guangdong’s medical products administration to import and deliver the therapy, is poised to play a crucial role in the drug’s distribution. Fremanezumab was first administered at Guangzhou United Family Hospital in early July, marking a significant step in improving access to this therapy for migraine sufferers in the area.
Supply Chain and Logistics Support
CR Guangdong’s capabilities in logistics delivery and supply chain management are expected to enhance the efficiency and reach of Teva’s fremanezumab in the GBA. This strategic partnership underscores the importance of robust distribution networks in ensuring that innovative therapies like fremanezumab are made available to patients who need them, thereby improving treatment outcomes and quality of life for those affected by migraines.-Fineline Info & Tech
